Results 121 to 130 of about 3,395 (155)
Some of the next articles are maybe not open access.
Alirocumab: First Global Approval
Drugs, 2015Alirocumab (Praluent®) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi that has been approved in the US as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic cardiovascular disease, who require ...
openaire +2 more sources
Alirocumab: A Review in Hypercholesterolemia
American Journal of Cardiovascular Drugs, 2016Alirocumab (Praluent(®)) is a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) that is administered via subcutaneous injection every 2 weeks. Across ten phase III studies from the ODYSSEY clinical trial program in patients with heterozygous familial hypercholesterolemia (heFH) or nonfamilial hypercholesterolemia (nonFH),
Sarah L, Greig, Emma D, Deeks
openaire +2 more sources
Alirocumab: targeting PCSK9 to treat hypercholesterolemia
Drugs of Today, 2015Lowering of low-density lipoprotein (LDL) cholesterol reduces coronary heart disease morbidity and mortality, not only in secondary but also in primary prevention. Statins are generally accepted as a treatment of choice for this. However, still many high-risk and very-high-risk patients fail to achieve target LDL cholesterol values.
I, Pećin, Ž, Reiner
openaire +2 more sources
Alirocumab for the treatment of hypercholesterolemia
Expert Opinion on Biological Therapy, 2017Alirocumab is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) that is administered by subcutaneous injection every 2 weeks. Area covered: Herein, the authors discuss the background to inhibition of PCSK9 and the pharmacodynamics, pharmacokinetics and clinical trials with alirocumab.
Brian, Tomlinson +4 more
openaire +2 more sources
Alirocumab-associated unilateral posterior uveitis
BMJ Case ReportsA man in his mid-40s who had been recently started on alirocumab (a human monoclonal antibody which inhibits proprotein convertase subtilisin/kexin type 9) due to his strong familial cardiovascular risk and refractory hypercholesterolaemia presented with a few-hour history of acute-onset left-sided blurred vision.
Ehinomen Sarah Inegbedion +3 more
openaire +2 more sources
Alirocumab: Pediatric First Approval
Pediatric DrugsAlirocumab (Praluent®), a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor that has been co-developed by Regeneron Pharmaceuticals, Inc. and Sanofi (formerly sanofi-aventis), is approved globally for use in adults with established cardiovascular disease, primary hyperlipidemia [including heterozygous familial hypercholesterolemia (HeFH ...
openaire +2 more sources